Share
18,417 Posts.
lightbulb Created with Sketch. 814
clock Created with Sketch.
28/03/17
13:54
Share
Originally posted by RAllen50
↑
I think what you are saying is true in terms of the IP, trials etc. However, from an investors perspective the multiple candidates can be seen as future cost and future liability. What is inherently uncertain is what the current cash pool will derive as an outcome.
If there was one candidate, just say Anisina, and ~$25m in the bank then I would expect a higher SP than today, as you would believe that with that money NRT could progress the drug to another stage. With multiple candidates this becomes uncertain.
As a potential investor I am interested in NRT but I would prefer to sit on the sidelines (even at these levels) until there is more clarity on the pathway and spend. This goes to the core of what I say for many other stocks. SPs generally go up if a company can introduce new investors not just satisfy current shareholders. At this stage, the SP is depressed because I don't think there are sufficient signals (e.g. news or clarity) for a good entry point for incoming investors.
Expand
RAllen, NRT has 3or 4 candidates in the pipeline
The cost of a clinical trial vary based on therapeutic area.
The average cost of clinical trials across all therapeutic areas in the US was around $30-40 million before approval (Phase 1+2+3) and roughly equivalent amount post approval (Phase 4). The total cost increases by few million dollars every year.
https://www.quora.com/How-much-do-clinical-trials-for-drugs-cost
Refer Table 1 Oncology for average cost for Phase 1 -Phase 4